Bulletin
Investor Alert

press release

Nov. 30, 2021, 7:30 a.m. EST

GT Biopharma Abstract on Novel B7-H3 Immune Checkpoint Targeting Broad Spectrum Solid and Hematologic Malignancies Accepted for Presentation at ESMO IO Congress 2021

BEVERLY HILLS, Calif., Nov. 30, 2021 /PRNewswire/ -- GT Biopharma, Inc. (the "Company") /zigman2/quotes/200365724/composite GTBP -0.36% , a clinical stage immuno-oncology company focused on developing innovative therapeutics based on the Company's proprietary natural killer (NK) cell engager, TriKE® protein biologic technology platform, today announced that an abstract was accepted for presentation at the upcoming European Society for Medical Oncology ("ESMO") Immuno-Oncology ("IO") Congress 2021 to be held December 8-11, 2021 in Geneva Switzerland.

ESMO IO 2021 presentation details:

e-Poster Display Title (#126P):   Novel B7-H3 targeting dual nanobody NK cell engagers display robust activity against a broad spectrum of solid and hematologic malignancies

ESMO-IO will publish full abstracts on their website on Thursday, December 2 at 12:00 pm CET . GT Biopharma will post its poster on the company's website in the "Presentations"  section during the conference.

For abstract and event details please visit: https://www.esmo.org/meetings/esmo-immuno-oncology-congress-2021/programme

About Camelid Antibodies

Camelid antibodies  are single domain antibodies (sdAbs) from the Camelidae family of mammals that include llamas, camels, and alpacas. These animals produce 2 main types of antibodies. One type of antibody camelids produce is the conventional antibody that is made up of 2 heavy chains and 2 light chains. They also produce another type of antibody that is made up of only 2 heavy chains and no light chain. This is known as heavy chain IgG (hcIgG). While these antibodies do not contain the CH1 region, they retain an antigen binding domain called the VHH region. VHH antibodies, also known as single domain antibodies, contain only the VHH region from the camelid antibody. Camelid antibodies have key characteristics, which include high affinity and specificity (equivalent to conventional antibodies), high thermostability, good solubility and strictly monomeric behavior, small size, relatively low production cost, ease of genetic engineering, format flexibility or modularity, low immunogenicity, and a higher penetration rate into tissues.

About GTB-3650

GTB-3650 is the Company's lead second-generation Tri-Specific Killer Engager TriKE® program currently in preclinical development for the treatment of relapsed/refractory acute myelogenous leukemia (AML) and high-risk myelodysplastic syndrome (MDS).

About GT Biopharma, Inc.

GT Biopharma, Inc. is a clinical stage biopharmaceutical company focused on the development and commercialization of immuno-oncology therapeutic products based on our proprietary TriKE ® NK cell engager platform. Our TriKE ® platform is designed to harness and enhance the cancer killing abilities of a patient's immune system's natural killer cells. GT Biopharma has an exclusive worldwide license agreement with the University of Minnesota to further develop and commercialize therapies using TriKE ® technology. For more information, please visit gtbiopharma.com .

Forward-Looking Statements

This press release contains certain forward-looking statements that involve risks, uncertainties and assumptions that are difficult to predict, including statements regarding our clinical focus, and our current and proposed trials.  Words and expressions reflecting optimism, satisfaction or disappointment with current prospects, as well as words such as "believes", "hopes", "intends", "estimates", "expects", "projects", "plans", "anticipates" and variations thereof, or the use of future tense, identify forward-looking statements, but their absence does not mean that a statement is not forward-looking.  Our forward-looking statements are not a guarantee of performance, and actual results could differ materially from those contained in or expressed by such statements.  In evaluating all such statements, we urge you to specifically consider the various risk factors identified in our Annual Report on Form 10-K for the year ended December 31, 2020, our subsequent current reports on Form 8-K, our Quarterly Report on Form 10-Q for the quarter ended September 30, 2021, and our other filings with the Securities and Exchange Commission, any of which could cause actual results to differ materially from those indicated by our forward-looking statements.

Our forward-looking statements reflect our current views with respect to future events and are based on currently available financial, economic, scientific, and competitive data and information on current business plans.  You should not place undue reliance on our forward-looking statements, which are subject to risks and uncertainties relating to, among other things:  (i) the sufficiency of our cash position and our ongoing ability to raise additional capital to fund our operations, (ii) our ability to complete our contemplated clinical trials, or to meet the FDA's requirements with respect to safety and efficacy, (iii) our ability to identify patients to enroll in our clinical trials in a timely fashion, (iv) our ability to achieve approval of a marketable product, (v) design, implementation and conduct of clinical trials, (vii) the results of our clinical trials, including the possibility of unfavorable clinical trial results, (vii) the market for, and marketability of, any product that is approved, (viii) the existence or development of treatments that are viewed by medical professionals or patients as superior to our products, (ix) regulatory initiatives, compliance with governmental regulations and the regulatory approval process, and social conditions, and (x) various other matters, many of which are beyond our control.  Should one or more of these risks or uncertainties develop, or should underlying assumptions prove to be incorrect, actual results may vary materially and adversely from those anticipated, believed, estimated, or otherwise indicated by our forward-looking statements.

We intend that all forward-looking statements made in this press release will be subject to the safe harbor protection of the federal securities laws pursuant to Section 27A of the Securities Act, to the extent applicable.  Except as required by law, we do not undertake any responsibility to update these forward-looking statements to take into account events or circumstances that occur after the date of this press release.  Additionally, we do not undertake any responsibility to update you on the occurrence of any unanticipated events which may cause actual results to differ from those expressed or implied by these forward-looking statements.

TriKE ® is a registered trademark owned by GT Biopharma, Inc. 

Investor Relations Contacts:  GT Biopharma-Investor Relations Consultant  David Castaneda                                           David@gtbiopharma.com                           414-351-9758 

LifeSci Advisors Corey Davis, Ph.D.cdavis@lifesciadvisors.com212-915-2577                                          

Cision
View original content to download multimedia: https://www.prnewswire.com/news-releases/gt-biopharma-abstract-on-novel-b7-h3-immune-checkpoint-targeting-broad-spectrum-solid-and-hematologic-malignancies-accepted-for-presentation-at-esmo-io-congress-2021-301433739.html

SOURCE GT Biopharma, Inc.

COMTEX_398012876/2454/2021-11-30T07:30:13

Is there a problem with this press release? Contact the source provider Comtex at editorial@comtex.com. You can also contact MarketWatch Customer Service via our Customer Center.

Copyright (C) 2021 PR Newswire. All rights reserved

/zigman2/quotes/200365724/composite
US : U.S.: Nasdaq
$ 2.79
-0.01 -0.36%
Volume: 35,953
Aug. 5, 2022 4:00p
P/E Ratio
N/A
Dividend Yield
N/A
Market Cap
$85.10 million
Rev. per Employee
N/A
loading...

Comtex

Partner Center

Link to MarketWatch's Slice.